The Human Leukocyte Antigen (HLA) genes are those which are responsible
for detecting foreign substances and triggering the immune system. Such
HLA screening includes the detection of drug molecules, bacteria and
viruses as well as the process of self recognition, such as the
screening of tumor cells and autoimmunity. HLA variation is, of course,
also the basis for organ transplant rejection. As a result, complex HLA
genetic testing is now the standard of care for all of transplantation
medicine, performed on @100,000 individuals per year worldwide and, as
such, is the recognized gold standard for the field of personalized
medicine. It has also been widely
READ MORE
|
Applied genetics is unique in laboratory medicine in terms of the
extensive sample preparation and subsequent sample QC required before
analysis can be initiated. Some estimates suggest that the “DNA
purification problem” can contribute to as much as ½ of the time and
cost associated with routine genetic testing. gmsbiotech has developed
a new technology, coupled to high resolution HLA typing, which
completely bypasses DNA purification and quantitation, thus allowing
HLA typing directly from raw blood (rehydrated) dried blood spots on
Guthrie cards and from raw buccalswabs. This new,
“purification free” approach to HLA typing will be launched as product
in early 2011.
|
gmsbiotech has established several academic and industrial
collaborations to apply and validate its patented technology in HLA
typing. Based on its central role in vaccination responsiveness,
infectious disease susceptibility, inflammatory disease risk and organ
or stem cell transplantation, HLA-typing could become the first complex
genetic text that is given universally among a healthy population,
perhaps at birth. It is the gms mission to enable such population scale
HLA-typing, by implementing its low cost microarray technology on raw,
unpurified samples such as whole blood, dried blood spots and raw cheek
swabs, thus completely bypassing costly and time consuming DNA
purification steps.
gmsbiotech welcomes collaborations to accomplish this ambitious goal.
|
|
gmsbiotech
(gms) has developed a plan to penetrate the new and rapidly growing
personalized medicine marketplace, based on the development of its
unique micro array technology. The beach-head product in this market is
"The HLA Chip" which is based on Human Leukocyte Antigen (HLA) typing:
with proven market applications for tissue transplantation and stem
cell therapeutics; and early stage but high- growth- potential markets,
also based on HLA analysis, for vaccine development, personalized
vaccine delivery, personalized treatment for autoimmune diseases (MS,
Arthritis), and personalized treatment of microbial infection.
Follow-on gmsbiotech products in the personalized medicine market will
service chemical therapeutics: especially those applications where
personal genetic variation at a number of gene sites can cooperate to
alter treatment
READ
MORE |
|
